ArticleOxford medical case reports2026
Adjuvant volumetric modulated arc therapy for incompletely resected type II pleuropulmonary blastoma: a case report.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPleuropulmonary blastoma (PPB) is a rare and aggressive pediatric thoracic malignancy within the DICER1 syndrome spectrum. Despite well-established multimodal treatment based on surgery and chemotherapy, evidence guiding the use of adjuvant radiotherapy remains scarce, given the rarity of this tumor. CASE REPORT: A 3-year-old girl with type II PPB, presenting with recurrent pyopneumothorax, achieved a 76% tumor reduction after seven cycles of IVADo chemotherapy, allowing incomplete surgical resection with residual viable tumor. Adjuvant VMAT (45 Gy/25 fractions) achieved excellent target coverage with organ sparing and was well tolerated (grade 2 radiodermatitis only), and the patient remained disease-free at 9 months.
conclusionThis case highlights the feasibility of modern VMAT-based adjuvant radiotherapy for incompletely resected type II PPB and illustrates how advanced treatment planning can optimize local control while limiting radiation exposure to critical organs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.